Российское сообщество больных Гепатитом С
Prev Chapter 3. TREATMENT (Conventional Medicine) Next

3.5.12 NCX-1000

Axcan Pharma’s NCX-1000 is a nitric oxide derivative of ursodiol, developed to treat portal hypertension, seen in late-stage liver disease. Phase I clinical trials in healthy patients should end in late 2003. The product reduces portal pressure by decreasing resistance inside the liver. It seems to reduce fibrosis and aptosis (self-destruction of liver cells) (www.newswire.ca/releases/February2003/05/c6843.html).

Prev Home Next
3.5.11 S-28463 (R-848; VML-600) Up 3.6.0 TRANSPLANT



Яндекс цитирования

Сайт управляется системой uCoz